Today: 11 June 2026
Intel Shares Edge Up as AI Chip Trade Runs Into Hurdles

Intel Shares Edge Up as AI Chip Trade Runs Into Hurdles

New York, May 18, 2026, 10:04 EDT

Intel stock picked up some ground in early New York trading Monday after chip names tumbled last week. Traders looked at fresh analyst targets, remarks from President Donald Trump on the government holding, and more arguments about how much is left in the AI trade.

The stock was last at $109.10, up 0.3%, after trading between $106.81 and $115.20. The iShares Semiconductor ETF slid 0.9%. Nvidia eased 0.2%. Advanced Micro Devices was unchanged.

Intel is more than a turnaround story now. The stock is seen as a gauge of whether people still have an appetite for AI trades linked to CPUs, the standard server and PC chips, or if the focus is still on GPU players like Nvidia.

Intel saw some gains after the open as the broader market lifted. The S&P 500 and Nasdaq rose in early trade, chip stocks moved up, and bond selling slowed, Reuters reported. Still, Friday’s losses lingered—Intel dropped 6.2% last session and the Philadelphia semiconductor index fell 4%. Traders pointed to inflation and higher Treasury yields as pressure.

Trump put a political spotlight on the stock, telling Fortune he “should have asked for more” from Intel for the U.S. government, according to Reuters. The Trump administration took a 10% stake in Intel last year and committed about $10 billion tied to U.S. manufacturing plans. Reuters reported the government stake in Intel is now above $50 billion. Reuters

Intel got fresh target hikes from Wall Street. Citi analyst Atif Malik lifted his price target to $130 from $95. Benchmark analyst Cody Acree moved to $140, Barron’s reported. Still, Intel looked set for a five-day slide in premarket trade before bouncing Monday, according to Barron’s.

Intel reported first-quarter revenue of $13.6 billion, up 7% from the prior year. The company guided for second-quarter revenue in a range of $13.8 billion to $14.8 billion. Its Data Center and AI business rose 22%, while Intel Foundry, the contract chip unit, booked a 16% increase.

Chief Executive Lip-Bu Tan said AI’s surge is “increasing the need for Intel’s CPUs.” Finance chief David Zinsner called it “unprecedented demand for silicon.” Intel reports both non-GAAP and GAAP earnings. The non-GAAP figures strip out certain costs management doesn’t count as core. Business Wire

Intel lost some ground in the server CPU market in the first quarter, with its share falling to 54.9%, UBS analysts told Barron’s. AMD picked up share at 27.4%, and Arm reached 17.7%. Even as AI demand picks up, Intel’s competitors keep cutting into its lead.

Valuation risk is also in focus. Michel Lerner, head of HOLT at UBS, said investors could be pricing AI firms like they’re “immune to normal competitive dynamics.” HOLT looks at company performance and valuation through cash flow return on investment, or cash profit versus capital in. Barron’s

Semiconductor stocks have rallied. The Philadelphia Semiconductor Index surged 64% since March 30, according to Reuters. Intel shares nearly tripled in the same stretch. Michael O’Rourke, chief market strategist at JonesTrading, told Reuters semiconductors now make up enough of the S&P 500 that “any correction or any disappointment creates risk” for the index as a whole. Reuters

Intel reports next on Tuesday, when Tan is scheduled to speak at the J.P. Morgan Global Technology, Media and Communications Conference. Investors are watching for more on Intel’s strategy, the manufacturing roadmap, and if AI demand will start to lift profit or just bump up revenue.

Intel faces a tough spot if bond yields stay high, oil pushes inflation, or AMD and Arm gain more ground in servers. Investors might not pay up for Intel’s future profit in that case. The stock could take a hit, even if the long-term AI bull case is still there.

Stock Market Today

  • US Stocks Rise on AI Gains as Oil Prices Steady Amid Iran War Concerns
    June 11, 2026, 10:56 AM EDT. US stock indices climbed on Thursday, led by artificial intelligence (AI) stocks driving gains in chipmakers like Marvell Technology (+4.3%) and Intel (+10.4%). The S&P 500 rose 0.6%, with the Nasdaq up 0.8% and the Dow gaining 0.7%. Despite escalating tensions in the Iran war, oil prices held steady, with Brent crude easing 1.1% to $92.08 per barrel and U.S. crude down 0.6% to $89.52. The market showed resilience despite concerns over inflation pressures fueled by higher wholesale prices and renewed geopolitical risks. Oracle fell 10.3% after announcing substantial planned borrowing and equity sales to fund AI investments, reflecting investor caution on aggressive spending amidst uncertainty.

Latest articles

Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention

Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention

11 June 2026
TOVX soared 74.6% to $0.4252 after Theriva Biologics published Phase 1 VCN-01 data showing survival and biomarker signals in head-and-neck cancer, but the jump was not due to drug approval or revenue; investors face ongoing financing, dilution, and clinical-trial execution risks, with the company’s cash runway only into Q1 2027 and substantial doubt about its ability to continue as a going concern without new capital.
Trulieve Stock Turns Heads on NYSE After $50 Million Buyback

Trulieve Stock Turns Heads on NYSE After $50 Million Buyback

11 June 2026
Trulieve began NYSE trading as TRLV this week after moving from OTC/CSE, authorized a buyback of up to $50 million or 8.5 million shares, and closed its first NYSE session at $11.50, down 0.43%, before trading near $11.78 early Thursday, as investors weigh whether the uplisting and buyback will boost demand amid ongoing federal cannabis policy uncertainty.
Propanc Biopharma Jumps on $5 Million Buyback Plan, Investors React

Propanc Biopharma Jumps on $5 Million Buyback Plan, Investors React

11 June 2026
Propanc Biopharma shares soared as much as 392% after authorizing up to $5 million in stock buybacks—exceeding its prior $3.1 million equity value—even as it reported just $443,702 in cash and flagged going-concern risks, with investors now focused on whether its lead cancer drug PRP will advance to a planned Phase 1b trial this year.
Hims & Hers Sinks Pre-Market After Debt Deal Fuels Dilution Talk
Previous Story

Hims & Hers Sinks Pre-Market After Debt Deal Fuels Dilution Talk

TSMC’s $1.5 Trillion AI Chip Move Pressures Samsung, Intel
Next Story

TSMC’s $1.5 Trillion AI Chip Move Pressures Samsung, Intel

Go toTop